Table 1.
Baseline characteristics of 56 patients.
| All | Placebo | Dex | P-value | |
|---|---|---|---|---|
| n = 56 (100%) | n = 30 (53.6%) | n = 26 (46.4%) | ||
| Age (years) | ||||
| Median [IQR] | 69 [65–75.5] | 69 [65–75] | 71.5 [62–76] | 0.928b |
| Sex | ||||
| Female | 16 (28.6%) | 9 (30%) | 7 (26.9%) | 0.799a |
| BMI, kg/m2 | ||||
| Median [IQR] | 27.1 [24.4–30.50] | 27,29 [24.9–32.10] | 26,78 [23.4–30] | 0.465b |
| ASA PS | ||||
| III + IV | 29 (51.8%) | 15 (50%) | 14 (53.8%) | 0.774a |
| Quantity of preoperative agents | ||||
| Median [IQR] | 5 [3–7] | 5 [3.8–6] | 5 [2.75-8] | 0.710b |
| Polypharmacy with ≥ 5 preoperative agents | ||||
| ADS | 31 (55.4%) | 17 (56.7%) | 14 (53.8%) | 0.832a |
| ≥ 1 | 8 (14.3%) | 3 (11.1%) | 5 (20%) | 0.375a |
| Type of surgery | ||||
| Abdominal | 44 (78.6%) | 24 (75.0%) | 20 (78.6%) | 0.780a |
| Cardiac | 12 (21.4%) | 6 (25%) | 6 (21.4%) | |
| Incision-suture time, hours | ||||
| Median [IQR] | 4.31 [3–5.83] | 4.45 [3.6–5.9] | 3.58 [2.45–5.8] | 0.135b |
| Applied volume of placebo/ Dex | ||||
| Median [IQR] | 83.20 [51.9–115.5] | 76.3 [59–111.6] | 84.8 [46–123.6] | 0.961b |
Statistical analysis was conducted between patients receiving standard general anaesthesia (Placebo) and dexmedetomidine in addition to general anaesthesia (Dex).
ASA PS American Society of Anaesthesiology Physical Score, BMI Body Mass Index, ADS anticholinergic drug scale of preoperative long-term medications, Dex dexmedetomidine, IQR interquartile range.
aCategorical variables analysed by Chi2 test.
bContinuous variables analysed by Mann–Whitney U test.